New biomarkers for checkpoint inhibitor therapy. (15th September 2020)

• Record Type: Journal Article
• Authors: Burdett, Nikki; Desai, Jayesh
• Is Part Of: ESMO open. Volume 5(2020)Supplement 1
• Publication Date: 2020-09-15
• Subjects: biomarker -- immunotherapy -- checkpoint inhibitor; Cancer -- Periodicals; 616.994005
• DOI: 10.1136/esmoopen-2019-000597
• Languages: English
• ISSNs: 2059-7029

Abstract

Abstract : Immune checkpoint inhibitor blockade has vastly changed treatment paradigms and improved outcomes of many solid organ malignancies. The achievements of the last decade have transformed the outcomes of several tumour types, most notably metastatic melanoma. There are, however, still large numbers of patients who receive checkpoint inhibitor therapy and do not respond. In addition to potential lack of efficacy, checkpoint inhibitors also come with a unique and sometimes devastating side-effect profile. There exists a strong need for biomarkers to accurately predict response, improve treatment selection and avoid exposing patients to toxicity where there is minimal likelihood of response. There is a wide range of methodologies investigating predictive biomarkers in this space; in this review, we address the major putative biomarkers of interest. These include conventional serum tests such as lymphocyte indices and lactate dehydrogenase, and more novel research markers such as interleukin-6 and T receptor clonality. We discuss tumorous factors that may be of interest in certain tumour types, and finally gene expression profiling. Significant research continues into many of these potential predictive biomarkers in response to the emergent need to better select patients who will benefit from treatment.